¿A quién beneficia el comercio paralelo de medicamentos en la Unión Europea?
Contenido principal del artículo
Resumen
Descargas
Detalles del artículo
Esta obra está bajo una https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es.
Creado a partir de la obra en http://www.eltrimestreeconomico.com.mx/index.php/te/index
Nota: la licencia de creative commons sólo aplica para la sección Artículos, para el contenido de las otras secciones, véase cada texto.
Métricas PlumX
Citas
Arfwedson, J. (2004), “Re-importation -Parallel Trade- in Pharmaceuticals, Institute for Policy Innovation”, Policy Report 182 (disponible en http://www.ipi.org).
Commission Communication on the Single Market in Pharmaceuticals, COM (1998) 5888 final, Bruselas.
Commission of the European Communities, Commission Communication on parallel imports of proprietary medicinal products for which marketing authorisations have already been agreed, Communication from the Commission, Bruselas, 30 de diciembre, COM(2003)839 final.
Costa-Font, J; P. Kanavos (2007), “Importaciones paralelas de medicamentos: El caso de la Simvastaina en Alemania, Holanda y el Reino Unido”, Gaceta Sanitaria 21, pp. 53-59.
--, y A. Burakoff (2002) “An Overview of Progress in the International Regulation of the Pharmaceutical Industry, Pierce Law Review 1, núm. 2, pp. 103-114.
Danzon, P. (1998), The Economics of Parallel Trade, Pharmacoeconomics, 13, pp. 293-304.
Ganslandt, M., y K. E. Maskus (2004), “Parallel Imports and the Pricing of Pharmaceutical Products: Evidence from the European Union, Journal of Health Economics, 23, pp. 1035-1057.
Hausman, J. A., y J. K. MacKie-Mason (1988), “Price Discrimination and Patent Policy”, RAND Journal of Economics, 19, pp. 253-265.
Jelovac, I., y C. Borodoy (2005), “Pricing and Welfare Implications of Parallel Imports in the Pharmaceutical Industry”, International Journal of Health Care Financing and Economics, 5, pp. 5-21.
Kanavos, Panos , Joan Costa-I-Font, Sherry Merkur y Marin Gemmill (2004), “The Economic Impact of Pharmaceutical Parallel Trade in European Union Member States: A Stakeholder Analysis LSE Health and Social Care”, London School of Economics and Political Science.
-- y J. Costa-Font (2005), “Pharmaceutical Parallel Trade in Europe: Impact on Stakeholders and Competition Effects”, Economic Policy, octubre.
Mauleg, D. y M. Schwartz (1994), “Parallel Imports, Demand Dispersion and International Price Discrimination”, Journal of International Economics.37, pp. 164-195.
Nazzini R (2003), “Parallel Trade in the Pharmaceutical Market – Trends and Future Solutions”, World Competition 26(1), pp. 53-74.
Rey, P. (2003), “The Impact of Parallel Imports on Prescription Medicines, mimeografiado.